Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.87 USD | +0.54% | +21.43% | +47.24% |
03:20pm | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
05-16 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.24% | 12.05M | |
+39.77% | 54.04B | |
+45.09% | 41.96B | |
-1.32% | 41.92B | |
-7.20% | 28.35B | |
+12.51% | 26.35B | |
-21.95% | 19B | |
+6.83% | 13B | |
+28.91% | 12.28B | |
+26.05% | 12.19B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- JonesTrading Downgrades Inhibikase Therapeutics to Hold From Buy